All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • Market intelligence reports
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 15, 2019
Home » Topics » Deals and M&A

Deals and M&A
%{topic} RSS Feed RSS

Puzzle-pieces-globe.png

Non-andante, Audentes: Gene therapy pace picking up with $3B Astellas buyout

December 3, 2019
By Randy Osborne
No Comments
Audentes Therapeutics Inc. CEO Matthew Patterson early last month characterized results with lead compound AT-132 in X-linked myotubular myopathy (XLMTM) as “unprecedented in neuromuscular disease,” and the value apparently wasn’t lost on Tokyo-based Astellas Pharma Inc., which signed a deal worth about $3 billion to take over the company. Shares of Audentes (NASDAQ:BOLD) closed at $58.93, up $30.32, or 106%, on word of the buyout – which pairs the two firms’ gene therapy expertise and is slated to close in the first quarter of next year – at a cost of $60 per share in cash.
Read More

Alteogen licenses ALT-B4 to a top 10 global pharma in potential $1B+ deal

December 3, 2019
By Jihyun Kim
No Comments
HONG KONG – South Korean company Alteogen Inc. signed a nonexclusive global license agreement with a top 10 global pharmaceutical company for its recombinant human hyaluronidase enzyme, ALT-B4, in exchange for an up-front payment of $13 million.
Read More

Astellas buying Audentes for $3B to create gene-therapy powerhouse

December 3, 2019
By Randy Osborne
No Comments

<p>Shares of Audentes Therapeutics Inc. (NASDAQ:BOLD) were trading pre-market at $58.97, up $30.36, or 106% on word of the takeover by Astellas Pharma Inc., which is paying $60 per share in cash for an equity value of about $3 billion.</p>


Read More
Novoheart-hvcoc-12-2.png

Novoheart, Astrazeneca to co-create stem cell-based heart failure model

December 2, 2019
By Meg Bryant
No Comments
Stem cell biotech firm Novoheart Holdings Inc., of Vancouver, British Columbia, is partnering with Astrazeneca plc, of Cambridge, U.K., to co-develop a human-specific in vitro, functional model of heart failure with preserved ejection fraction.
Read More
Novoheart-hvcoc-12-2.png

Novoheart, Astrazeneca to co-create stem cell-based heart failure model

December 2, 2019
By Meg Bryant
No Comments
Heart failure with preserved ejection fraction (HFpEF), also known as diastolic heart failure, accounts for roughly half of all heart failure cases worldwide. The condition, which occurs when the ventricles do not relax as they fill with blood following heart muscle contractions, is especially common in elderly women, striking up to 10% of those over 80 years old. Now stem cell biotech firm Novoheart Holdings Inc., of Vancouver, British Columbia, is partnering with Astrazeneca plc, of Cambridge, U.K., to co-develop a human-specific in vitro, functional model of HFpEF. The goal is to give drug researchers critical clues of a drug candidate’s efficacy before it is tested in patients.
Read More

Baxter set to pick up Seprafilm assets from Sanofi for $350M

December 2, 2019
By Liz Hollis
No Comments
Baxter International Inc., of Deerfield, Ill., has entered an agreement to acquire Seprafilm adhesion barrier and related assets from Paris-based Sanofi SA.
Read More
puzzle-merge-addition.png

Baxter set to pick up Seprafilm assets from Sanofi for $350M

December 2, 2019
By Liz Hollis
No Comments
Baxter International Inc., of Deerfield, Ill., has entered an agreement to acquire Seprafilm adhesion barrier and related assets from Paris-based Sanofi SA. The expected price at closing is $350 million, with the transaction anticipated to wrap up in the first quarter of 2020.
Read More

Neurocrine, Xenon in deal for $50M up front, up to $1.7B in milestones

December 2, 2019
By Lee Landenberger
No Comments
In its second large deal of the calendar year, Neurocrine Biosciences Inc. acquired the rights to Xenon Pharmaceutical Inc.’s selective sodium channel inhibitor for treating epileptic encephalopathy. Xenon receives $30 million up front, $20 million in equity and up to $1.7 billion in potential development, regulatory and commercial milestone payments.
Read More

GI Innovation licenses GI-101 to Simcere at maximum $796 million

December 2, 2019
By Jihyun Kim
No Comments
HONG KONG – Seoul, South Korea-based GI Innovation Inc. has licensed to Nanjing, Jiangsu-based Simcere Pharmaceutical Co. Ltd. rights to its immunotherapy drug candidate, G1-101, a bispecific CD80/interleukin2 (IL-2) variant fusion protein.
Read More

Immupharma signs Avion as commercialization partner for lupus drug Lupuzor

December 2, 2019
By Nuala Moran
No Comments
LONDON – Eight years after the first licensing deal unwound, Immupharma plc has found a new commercialization partner for its lupus treatment, Lupuzor.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 13 14 Next

Popular Stories

  • Bioworld MedTech’s Oncology Extra

    BioWorld MedTech
    Keeping you up to date on recent developments in oncology.
  • Ear-disorders

    FDA gives thumbs up to Cochlear’s implantable bone conduction hearing system

    BioWorld MedTech
    The U.S. FDA has cleared Cochlear Ltd.’s newest cochlear implant, the Osia 2 system, an active implantable bone conduction hearing system. Unlike Cochlear’s...
  • Drugs-pills-global-map-

    Analysis by U.K. startup Medbelle highlights extent of drug pricing disparity

    BioWorld
    LONDON – It’s no secret that American citizens pay the most for drugs, but the extent of the disparity is laid bare in a new index of the prices of 13 medicines...
  • Frankyoung-11-27

    Buoyed by optimism and love of family, former FDA chief Frank Young leaned into storms

    BioWorld
    Commissioner of the FDA for five years starting in 1984, Frank Young relished his position “at the vortex of controversy” as he sought to deal with the AIDS...
  • Biopharma companies continue their strong momentum in November

    BioWorld
    After being in the doldrums for the majority of the year, public biopharmaceutical companies, it appears, have turned the corner and are now on a major upswing.
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Archives
    • Contact us
    • Cookie policy
    • Copyright notice
    • Privacy policy
    • Share your news
    • Staff
    • Terms of use
Follow Us

Copyright ©2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing